Trial Profile
A PILOT STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY AND EFFICACY OF A DAILY DOSE OF 500MG. LU901 (4PHENYL-BUTYRATE, CONTROLLED RELEASE TABLETS) IN ADDITION TO STANDARD HORMONAL TREATMENT IN PATIENTS WITH METASTASIZED PROSTATE CARCINOMA AND A LIFE EXPECTANCY OF AT LEAST 6 MONTHS
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Dec 2015
Price :
$35
*
At a glance
- Drugs Sodium phenylbutyrate (Primary) ; Hormones
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors LUNAMeD AG
- 25 Jun 2011 New trial record